Abstract
Supplementation of certain calcium crystallization inhibitors, such as citrate and magnesium, and the dilution of urine with water are now considered consolidated practice for the prevention of calcium kidney stones. The aim of this study is to verify, using tried and true in vitro methods, whether the effect of these inhibitors can manifest itself in different ways depending on whether the urine is concentrated or diluted. Calcium oxalate crystallization was studied on 4-h urine of 20 male idiopathic calcium oxalate stone formers, first under low hydration conditions (non-diluted urine) and then under high hydration conditions (diluted urine). Both the diluted and the non-diluted urine samples were subjected to three types of load: (a) an oxalate concentration increment of 1.3 mmol/l only; (b) an oxalate concentration increment of 1.3 mmol/l with a citrate concentration increment of 1.56 mmol/l; (c) an oxalate concentration increment of 1.3 mmol/l with a magnesium concentration increment of 2.08 mmol/l. In non-diluted urine, the addition of the citrate and magnesium did not modify the crystallization parameters under study. In contrast, in the diluted urine the addition of the citrate and magnesium led to a reduction in the total quantity of crystals (equivalent to 35–45%) and their aggregates (equivalent to 30–40%); at the same time, there was an increase in the diameter of the monohydrate calcium oxalate crystals, which also underwent a morphological change. In conclusion, the inhibitory effects of citrate and magnesium on the crystallization of calcium oxalate do not manifest themselves in highly concentrated urine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borghi L, Guerra A, Meschi T, Briganti A, Schianchi T, Allegri F et al (1999) Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers. Kidney Int 55:1041–1050
Guerra A, Allegri F, Meschi T, Adorni G, Prati B, Nouvenne A et al (2005) Effects of urine diluition on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load. Clin Chem Lab Med 43(6):585–589
Pak CY, Sakhaee K, Crowther C, Brinkley L (1980) Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann Int Med 93:36–39
Frank M, De Vries A, Tikva P (1966) Prevention of urolithiasis: education to adequate fluid intake in a new town situated in the Judean desert mountains. Arch Environ Health 13:625–630
Borghi L, Meschi T, Amato A, Briganti A, Novarini A, Giannini A (1996) Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-years randomized prospective study. J Urol 155(3):839–843
Pak CY, Koenig K, Khan R, Haynes S, Padalino P (1992) Physicochemical action of potassium–magnesium citrate in nephrolithiasis. J Bone Miner Res 7(3):281–285
Barcelo P, Wuhl O, Servitge A, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150:1761–1764
Pak CY (1994) Citrate and renal calculi: an update. Miner Electrolyte Metab 20:371–377
Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium–magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158:2069–2073
Werness PG, Brown CM, Smith LH, Finlayson B (1985) Equil2: a basic computer program for the calculation of urinary saturation. J Urol 134:1242–1244
Koenig K, Padalino P, Alexandrides G, Pak CY (1991) Biovailability of potassium and magnesium, and citraturic response from potassium–magnesium citrate. J Urol 145:330–334
Guerra A, Meschi T, Allegri F, Schianchi T, Adorni G, Novarini A et al (2004) Calcium oxalate crystallization in untreated urine, centrifugeted and filtered urine and ultrafiltered urine. Clin Chem Lab Med 42(1):45–50
Kok DJ, Papapoulos SE, Bijvoet OLM (1986) Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 10:1056–1058
Kok DJ, Papapoulos SE, Bijvoet OLM (1990) Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 37:51–56
Grases F, Costa-Bauza A (1990) Study of factors affecting calcium oxalate crystalline aggregation. Br J Urol 66:240–244
Tiselius HG, Fornander AM, Nilsson MA (1993) The effects of citrate and urine on calcium oxalate crystal aggregation. Urol Res 21:363–366
Lieske JC, Coe FL (1996) Urinary inhibitors and renal stone formation. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott-Raven, Philadelphia, pp 65–113
Schwille PO, Schmiedl A, Herrmann U, Fan J, Gottlieb D, Manoharan M, Wipplinger J (1999) Magnesium, citrate, magnesium citrate and magnesium–alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 27:117–126
Antinozzi PA, Brown CM, Purich DL (1992) Calcium oxalate monohydrate cristallization: citrate inhibition of nucleation and growth step. J Crystal Growth 125:215–222
Hess B, Kok DJ (1996) Nucleation growth, and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott-Raven, Philadelphia, pp 3–32
Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR (2004) Tamm–Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166
Hess B (1992) Tamm–Horfall glycoprotein-inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 20:83–86
Hess B, Zipperle L, Jaeger P (1993) Citrate and calcium effects on Tamm–Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784–F791
Khan SR (1997) Interactions between stone-forming calcific crystals and macromolecules. Urol Int 59:59–71
Hess B, Jordi S, Zipperle L, Ettinger E, Giovanoli R (2000) Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm–Horsfall protein of a healthy subject and a severely recurrent calcium stone former. Nephrol Dial Transplant 15:366–374
Coe FL, Nakagawa Y, Asplin J, Parks JH (1994) Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab 20:378–384
Guerra A, Meschi T, Schianchi T, Allegri A, Novarini A, Borghi L (2002) Crystalline aggregation in vitro: interaction between urinary macromolecules and the micromolecular environment. Acta Biomed Ateneo Parmense 73(1–2):11–26
Millan A (1997) Crystal morphology and texture in calcium oxalate monohydrate renal calculi. J Mater Sci Mater Med 8(5):247–250
Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH et al (2004) Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 101(7):1811–1815
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guerra, A., Meschi, T., Allegri, F. et al. Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load. Urol Res 34, 359–364 (2006). https://doi.org/10.1007/s00240-006-0067-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00240-006-0067-z